Author: Jean, Shio-Shin; Lee, Ping-Ing; Hsueh, Po-Ren
Title: Treatment options for COVID-19: The reality and challenges Cord-id: j8n06hzx Document date: 2020_4_4
ID: j8n06hzx
Snippet: An outbreak related to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, China in December 2019. An extremely high potential for dissemination resulted in the global coronavirus disease 2019 (COVID-19) pandemic in 2020. Despite the worsening trends of COVID-19, no drugs are validated to have significant efficacy in clinical treatment of COVID-19 patients in large-scale studies. Remdesivir is considered the most promising antiviral agent; it works by in
Document: An outbreak related to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, China in December 2019. An extremely high potential for dissemination resulted in the global coronavirus disease 2019 (COVID-19) pandemic in 2020. Despite the worsening trends of COVID-19, no drugs are validated to have significant efficacy in clinical treatment of COVID-19 patients in large-scale studies. Remdesivir is considered the most promising antiviral agent; it works by inhibiting the activity of RNA-dependent RNA polymerase (RdRp). A large-scale study investigating the clinical efficacy of remdesivir (200 mg on day 1, followed by 100 mg once daily) is on-going. The other excellent anti-influenza RdRp inhibitor favipiravir is also being clinically evaluated for its efficacy in COVID-19 patients. The protease inhibitor lopinavir/ritonavir (LPV/RTV) alone is not shown to provide better antiviral efficacy than standard care. However, the regimen of LPV/RTV plus ribavirin was shown to be effective against SARS-CoV in vitro. Another promising alternative is hydroxychloroquine (200 mg thrice daily) plus azithromycin (500 mg on day 1, followed by 250 mg once daily on day 2–5), which showed excellent clinical efficacy on Chinese COVID-19 patients and anti-SARS-CoV-2 potency in vitro. The roles of teicoplanin (which inhibits the viral genome exposure in cytoplasm) and monoclonal and polyclonal antibodies in the treatment of SARS-CoV-2 are under investigation. Avoiding the prescription of non-steroidal anti-inflammatory drugs, angiotensin converting enzyme inhibitors, or angiotensin II type I receptor blockers is advised for COVID-19 patients.
Search related documents:
Co phrase search for related documents- acceptable alternative and acute respiratory distress syndrome: 1, 2, 3, 4
- acceptable alternative and lopinavir ritonavir: 1
- ace inhibitor and acute ards respiratory distress syndrome: 1, 2, 3, 4
- ace inhibitor and acute respiratory distress syndrome: 1, 2, 3, 4, 5
- acinetobacter pseudomonas aeruginosa and acute ards respiratory distress syndrome: 1, 2
- acinetobacter pseudomonas aeruginosa and acute respiratory distress syndrome: 1, 2
- acinetobacter pseudomonas aeruginosa klebsiella pneumoniae and acute ards respiratory distress syndrome: 1, 2
- acinetobacter pseudomonas aeruginosa klebsiella pneumoniae and acute respiratory distress syndrome: 1, 2
- acute ards respiratory distress syndrome and administer dose: 1
- acute ards respiratory distress syndrome and liver enzyme: 1, 2, 3, 4
- acute ards respiratory distress syndrome and long hospitalization: 1
- acute ards respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory distress syndrome and administer dose: 1
- acute respiratory distress syndrome and liver enzyme: 1, 2, 3, 4, 5, 6
- acute respiratory distress syndrome and load reduction: 1, 2
- acute respiratory distress syndrome and long hospitalization: 1
- acute respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- liver enzyme and lopinavir ritonavir: 1, 2, 3, 4
- load reduction and lopinavir antiviral activity: 1, 2
Co phrase search for related documents, hyperlinks ordered by date